Latest Fecal bacteriotherapy Stories
In five different studies presented at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, researchers explored the impact of various factors on increasing rates of Clostridium difficile infection (C. difficile), such as the use of proton pump inhibitors (PPIs) and the substantial increase in antibiotic use due to new National Hospital Quality Measures; strategies to combat high rates of C. difficile infections; and cutting"edge treatments for...
Greater understanding of genetics of ulcerative colitis key to developing new treatments, researchers sayLOS ANGELES -- A study of the human genome led by Cedars-Sinai researchers has now identified genes linked to ulcerative colitis, offering clues as to what causes the condition and potential avenues for new therapies to treat the disease. The study, published in Nature Genetics, examined genes of nearly 13,000 patients to determine which parts of the genome are linked to ulcerative...
SAN DIEGO, Feb. 4 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced positive top-line results from the second of two pivotal Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI). This study was conducted in approximately 100 clinical sites throughout North America and Europe. The Company plans to use data from this study to support submission of a New Drug Application (NDA) to...
Some Oklahoma City doctors have begun giving fecal transplants to combat possibly deadly superbugs found in patients' colons, hospital officials say. The procedure is reported well known in other countries but new to the United States. Integris Baptist Medical Center doctors recently gave fecal transplants to three patients suffering from Clostridium difficile, also known as C-diff, the most common cause of infectious diarrhea in hospitals and nursing homes. The Centers for Disease Control...
In mice, recovery of microbiota that aid immune system is slow, incompleteIt's common knowledge that a protective navy of bacteria normally floats in our intestinal tracts. Antibiotics at least temporarily disturb the normal balance. But it's unclear which antibiotics are the most disruptive, and if the full array of "good bacteria" return promptly or remain altered for some time.In studies in mice, University of Michigan scientists have shown for the first time that two different types of...
At least three people died at a British hospital in an infectious outbreak that may be responsible indirectly for another 10 deaths, authorities say. Seventeen people were being treated for infection with clostridium difficile in an isolation ward at Eastbourne District General Hospital, The Daily Telegraph reported Tuesday. The hospital announced the deaths this week. C. difficile is normal in the human digestive system but multiplies when treatment with antibiotics disturbs the normal...
U.S. scientists discovered that researchers have been focusing on the wrong toxin in fighting the potentially deadly superbug Clostridium difficile. Study co-author Dr. Dale Gerding, a professor at Loyola University's Stritch School of Medicine, said the discovery might lead to new ways to combat the bacterium and its toxin, which can cause severe diarrhea and life-threatening colitis that could lead to the surgical removal of the colon. For 20 years, we have been focusing on Toxin A. But it...
According to Optimer Pharmaceuticals, its lead anti-infective drug candidate, OPT-80, showed higher clinical cure, global cure and recurrence rates in Phase III trials for the treatment of Clostridium difficile than the current standard of care, Vancocin. As a result, Datamonitor believes that OPT-80 has the potential to satisfy the large unmet need for an improved C. difficile treatment. Optimer Pharmaceuticals has released positive top-line results from a pivotal Phase III clinical study...
